Santaris Pharma
Biopharmaceutical company focused on the discovery and development of rna-targeted therapies.
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | 15 % | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 22 % | - | - | - | - |
Source: Company filings or news article
Related Content
Santaris is a pioneering healthcare company dedicated to addressing the global crisis of antimicrobial resistance and advancing personalized cancer care. Operating in the biotechnology and pharmaceutical sectors, Santaris collaborates with healthcare systems, industry partners, NGOs, governments, and regulatory bodies worldwide. The company serves a diverse range of clients, including hospitals, research institutions, and healthcare providers, aiming to improve patient outcomes through innovative solutions and cutting-edge research.
Santaris's business model revolves around developing and commercializing novel therapeutics and diagnostic tools. By leveraging strategic partnerships and a robust R&D pipeline, the company generates revenue through product sales, licensing agreements, and collaborative research funding. Santaris's commitment to global collaboration and innovation positions it as a leader in the fight against infectious diseases and cancer.
Keywords: antimicrobial resistance, personalized healthcare, cancer care, biotechnology, pharmaceuticals, global collaboration, diagnostics, therapeutics, R&D, healthcare innovation.